



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**2014 Annual Report and  
Notice of Annual General Meeting**

**London: Monday, 23 March 2015:** Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med ([www.chi-med.com](http://www.chi-med.com)).

**Ends**

**Enquiries**

**Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

**Panmure Gordon (UK) Limited**

Richard Gray  
Andrew Potts

Telephone: +44 20 7886 2500

**Citigate Dewe Rogerson**

Anthony Carlisle  
David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

**About Chi-Med**

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).